Availability, price and affordability of cardiovascular medicines: A comparison across 36 countries using WHO/HAI data

BMC Cardiovascular Disorders

Volumn 10, Issue , 2010, Pages

  van Mourik, Maaike S M ^a,b   Cameron, Alexandra ^b,c   Ewen, Marg ^d   Laing, Richard O ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c UTRECHT UNIVERSITY   (Netherlands)

^d Vancouver BC   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; CAPTOPRIL; CARDIOVASCULAR AGENT; HYDROCHLOROTHIAZIDE; LOSARTAN; NIFEDIPINE;

ARTICLE; CARDIOVASCULAR DISEASE; DEVELOPING COUNTRY; DRUG COST; HEALTH CARE POLICY; HEALTH SURVEY; HYPERTENSION; INCOME; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION; COMPARATIVE STUDY; COST OF ILLNESS; ECONOMICS; HEALTH CARE DELIVERY; HUMAN;

ANTIHYPERTENSIVE AGENTS; ATENOLOL; CAPTOPRIL; CARDIOVASCULAR DISEASES; COST OF ILLNESS; DEVELOPING COUNTRIES; HEALTH SERVICES ACCESSIBILITY; HUMANS; HYDROCHLOROTHIAZIDE; LOSARTAN; NIFEDIPINE; WORLD HEALTH ORGANIZATION;

EID: 77953212880     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-10-25     Document Type: Article

References (32)

1. World Health Organization The Global Burden of Disease 2004 Update. Geneva, Switzerland 2008, World Health Organization.
2. World Health Organization Preventing chronic disease: A vital investment: overview. Geneva, Switzerland 2005, World Health Organization.
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006, 3:e442. 10.1371/journal.pmed.0030442, 1664601, 17132052.
4. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001, 104:2746-2753. 10.1161/hc4601.099487, 11723030.
5. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002, 360:2-3. 10.1016/S0140-6736(02)09358-3, 12114031.
6. Mendis S, Abegunde D, Yusuf S, Ebrahim S, Shaper G, Ghannem H, Shengelia B. WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE). Bull World Health Organ 2005, 83:820-829. 2626468, 16302038.
7. Calvo-Vargas CG, Parra CJ, Grover PF, Fonseca RS. Changes in the costs of antihypertensive medications in a developing country: a study in Mexico comparing 1990 and 1996. Am J Hypertens 1998, 11:487-493. 10.1016/S0895-7061(97)00459-7, 9607388.
8. Buabeng OB, Matowe L, Plange-Rhule J. Unaffordable drug prices: the major cause of non-compliance with hypertension medication in Ghana. Journal of Pharmacy and Pharmaceutical Sciences 2004, 7:350-352.
9. Nurgozhin T, Pavin M, Hafner G, Yusupov F, Khusanbaev S, Laing R. Technical report: The Pharmaceutical Study in Ferghana Oblast, Uzbekistan 2001, Ferghana Oblast, Uzbekistan.
10. Hafner G, Nurgozhin T, Gulyaev A, Laing R. Technical report: Summary of Results: Availability of Pharmaceuticals in Kazakhstan's Pharmacies. Almaty, Kazakhstan 2002,
11. Guerra AA, Acurcio FA, Gomes CA, Miralles M, Girardi SN, Werneck GA, Carvalho CL. Availability of essential drugs in two regions of Minas Gerais, Brazil. Rev Panam Salud Publica 2004, 15:168-175.
12. Nobrega OT, Marques AR, de Araujo AC, Karnikowski MG, Naves JO, Silver LD. Retail prices of essential drugs in Brazil: an international comparison. Rev Panam Salud Publica 2007, 22:118-123. 10.1590/S1020-49892007000700006, 17976278.
13. Gelders S, Ewen M, Noguchi N, Laing R. Price, availability and affordability: An international comparison of chronic disease medicines. Cairo, Egypt 2006,
14. Mendis S, Fukino K, Cameron A, Laing R, Filipe A, Khatib O, Leowski J, Ewen M. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ 2007, 85:279-288. 10.2471/BLT.06.033647, 2636320, 17546309.
15. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet 2009, 373:240-249. 10.1016/S0140-6736(08)61762-6, 19042012.
16. WHO/HAI Measuring medicine prices, availability, affordability and price components. Geneva, Switzerland 2003, 1, WHO/HAI.
17. WHO/HAI Measuring medicine prices, availability, affordability and price components. Geneva, Switzerland 2008, 2, WHO/HAI.
18. Drug Price Indicator Guide [Homepage on the Internet]. , http://erc.msh.org/mainpage.cfm?file=1.0.htm&module=DMP&language=english
19. Electronic Orange Book. , http://www.fda.gov/cder/ob/default.htm
20. Medicine prices [Database on the Internet]. , http://www.haiweb.org/medicineprices/
21. International Monetary Fund World Economic Outlook Database [Database on the internet]. Washington DC 2007, 11-9-2007, International Monetary Fund., http://www.imf.org/external/pubs/ft/weo/2007/01/data/weoselgr.aspx
22. Country Classification [homepage on the Internet]. , http://go.worldbank.org/K2CKM78CC0
23. Ministry of Health & Family Welfare GoI National List of Essential Medicines 2003. New Delhi, India 2003, Ministry of Health & Family Welfare GoI.
24. Survey reports for Mongolia, Morocco and Nigeria. , http://www.haiweb.org/medicineprices/surveys.php
25. Niens LM, Brouwer WB. Better measures of affordability required. Lancet 2009, 373:1081-1082. 10.1016/S0140-6736(09)60649-8, 19329001.
26. Olcay ML, Laing R. Pharmaceutical Tariffs: What is their effect on prices, protection of local industry and revenue generation?. 2005, Geneva, Switzerland: WHO.
27. Working paper 419: Affordability of Pharmaceutical Drugs in Developing Countries. , http://www.econ.kuleuven.be/public/ndcalc9/Caldera_Zarnic_WP_IFW.pdf
28. Lopert R, Lang DL, Hill SR, Henry DA. Differential pricing of drugs: a role for cost-effectiveness analysis?. Lancet 2002, 359:2105-2107. 10.1016/S0140-6736(02)08911-0, 12086780.
29. World Health Organization and World Trade Organization Secretariats Report of the Workshop on Differential Pricing and Financing of Essential Drug. Geneva, Switzerland 2001, World Health Organization and World Trade Organization Secretariats.
30. World Health Organization Regional Office for the Eastern Meditteranean Syrian Arab Republic: Medicine prices, availability, affordability and price components. Cairo, Egypt 2008, World Health Organization Regional Office for the Eastern Meditteranean.
31. Survey report China Shandong. , http://www.haiweb.org/medicineprices/surveys.php
32. Survey report China Shanghai. , http://www.haiweb.org/medicineprices/surveys.php